Gregg Gerety, MD
Endocrinology, Diabetes & Metabolism · Albany, NYNPI 1881691152
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $285,907 of the $345,258 with a category attached, or 82.8%. 37 manufacturers reported payments, led by Dexcom, Inc. at 41.6% of the total. Reporting peaked in 2019 at $135,310 and has fallen 76.8% since, to $31,330 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 909 payments — averaging $379.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$144K
- Lilly USA, LLC$134K
- Novo Nordisk$57K
- Johnson & Johnson$3K
- Eli Lilly$1K
- Novo Nordisk AS$925
- plus $5K from 31 others
Across 1,018 payments — averaging $887.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$903K
What the payments were for
- Consulting fees$10,6953%
- Speaking & faculty fees$285,90783%
- Travel & lodging$34,37710%
- Food & beverage$14,1414%
- Education$790%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 145 | $143,593 |
| Lilly USA, LLC | 288 | $133,674 |
| Novo Nordisk | 130 | $57,384 |
| Johnson & Johnson | 17 | $3,070 |
| Eli Lilly | 2 | $1,239 |
| Novo Nordisk AS | 3 | $925 |
| Amgen | 65 | $819 |
| Abbott | 38 | $767 |
| Insulet Corporation | 47 | $751 |
| Sanofi-aventis U.S. LLC | 35 | $438 |
| AstraZeneca(2 entities) | 27 | $427 |
| AbbVie | 17 | $335 |
| Mannkind Corporation | 13 | $245 |
| Medtronic | 2 | $180 |
| Ipsen Biopharmaceuticals, Inc | 8 | $168 |
| Regeneron Healthcare Solutions, Inc. | 15 | $127 |
| IBSA Pharma Inc. | 7 | $126 |
| Boehringer Ingelheim | 8 | $123 |
| Pfizer | 4 | $116 |
| Senseonics, Incorporated | 3 | $101 |
| Tandem Diabetes Care, Inc. | 2 | $93 |
| Corcept Therapeutics | 6 | $90 |
| BETA Bionics, Inc. | 1 | $80 |
| Novartis | 4 | $61 |
| Radius Health, Inc. | 4 | $60 |
| Merck | 3 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Lifescan, Inc. | 2 | $31 |
| Bayer | 2 | $27 |
| Antares Pharma, Inc. | 2 | $27 |
| RGH Enterprises LLC | 1 | $19 |
| Embecta Corp. | 1 | $18 |
| BD | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$93,527
- DEXCOM G7 GSS (161)$66,734
- DEXCOM G6 TRANSMITTER$62,572
- BAQSIMI$31,219
- DEXCOM STELO GLUCOSE BIOSENSOR$30,742
- Tresiba$25,672
- Ozempic$19,289
- DEXCOM G6 CGM SYSTEM$8,333
- RYBELSUS$7,370
- DEXCOM CGM$4,916
- INVOKANA$2,880
- Xultophy 100/3.6$2,316
- MINIMED 780G$172
How this compares
$345,258 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 16 | $652,459 |
| OzempicSemaglutide | 347 | $598,053 |
| JardianceEmpagliflozin | 292 | $338,086 |
| TrulicityDulaglutide | 166 | $264,103 |
| MounjaroTirzepatide | 192 | $256,333 |
| FarxigaDapagliflozin Propanediol | 150 | $182,820 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 85 | $109,189 |
| JanuviaSitagliptin Phosphate | 51 | $80,097 |
| Repatha SureclickEvolocumab | 81 | $78,573 |
| TymlosAbaloparatide | 15 | $78,380 |
| FiaspInsulin Aspart (Niacinamide) | 43 | $63,529 |
| TradjentaLinagliptin | 57 | $51,434 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $45,893 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $43,620 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 203 | $43,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog, Rybelsus | $57,384 | $733,938496 claims |
| Corcept TherapeuticsKorlym | $90 | $652,45916 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev | $133,674 | $529,781369 claims |
| Boehringer IngelheimJardiance, Tradjenta | $123 | $389,520349 claims |
| AstraZenecaFarxiga | $427 | $182,820150 claims |
| MerckJanuvia, Janumet, Janumet Xr | $38 | $126,30194 claims |
| Radius Health, Inc.Tymlos | $60 | $78,38015 claims |
| PfizerEliquis | $116 | $32,79523 claims |
| AbbVieSynthroid | $335 | $20,914298 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $17,303969 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Albany
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.